{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":34,"description":"Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy\n\nCetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor\n\nCisplatin: Cisplatin is an anti-cancer chemotherapy drug\n\nNab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation\n\nintensity-modulated radiation therapy: intensity-modulated radiation therapy","id":"EG000","otherNumAffected":32,"otherNumAtRisk":34,"seriousNumAffected":3,"seriousNumAtRisk":34,"title":"Nab-Paclitaxel, Cisplatin, Cetuximab and Radiation Therapy"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":34,"numEvents":7}],"term":"hypothyroidism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":34,"numEvents":15}],"term":"larynx edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":34,"numEvents":10}],"term":"xerostomia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":34,"numEvents":4}],"term":"fibrosis"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1}],"term":"Nab-Paclitaxel toxicity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":34,"numEvents":2}],"term":"grade 4 larynx edema"}],"timeFrame":"Through study completion, and average of 2 years."}